Loading...
NPI 1750944526 · Blue Bell, PA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Silverpath, Inc. is a clinical medical laboratory provider located in Blue Bell, Pennsylvania. This profile covers 29 Medicare and 44 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Silverpath, Inc. |
| Address | 512 E. Township Line Road |
| City | Blue Bell |
| State | PA |
| ZIP | 19422 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 17, 2019 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $41.9M |
| Medicaid | $1M |
The provider appears to operate as a high-throughput molecular diagnostics laboratory: Medicare billing is dominated by amplified nucleic acid probe tests across a broad set of infectious agents (examples in the Medicare top codes include 87798, 87481, 87653, 87641 and multiplex panels such as 87631), and the Medicaid top codes show a similar molecular testing mix. Presence of panel and algorithmic tests like 87631 and 81514 further indicate capability for multiplex respiratory and algorithm-driven bacterial vaginosis analyses rather than only single-analyte testing.
Medicare revenue is highly concentrated: the precomputed top-three Medicare codes account for 74.5% of this provider’s $41.9M Medicare revenue, with 87798 alone representing $23.3M (56.3%) and 87481 contributing $6M (14.5%). This concentration shows dependency on a small number of high-volume molecular assays to drive the majority of Medicare receipts.
On Medicaid the revenue concentration is also substantial: the precomputed top-three Medicaid codes account for 68.2% of $1M total Medicaid revenue, led by 87798 at $533.7K (52.8%) and 87481 at $114.6K (11.3%). The Medicaid mix mirrors Medicare in focusing on the same molecular infectious-disease assays, although at a far smaller absolute dollar scale.
The provider’s payer mix is heavily Medicare-dominant: total Medicare revenue of $41.9M far exceeds total Medicaid revenue of $1M, indicating this entity is effectively scaled to serve Medicare volumes and is not a balanced dual-payer operation. Analysts should treat Medicaid as a small secondary payer when evaluating revenue risk and contract leverage.
Competitive standing on key molecular tests is national leadership for several codes: the provider ranks #1 nationally for 87798 and 87481 (100th percentile) and is labeled an "extreme outlier" for many other high-volume codes, which signals exceptionally large national volumes for specific amplified-probe assays compared with peers. This pattern identifies the provider as a dominant national player for certain nucleic-acid tests rather than a modest local lab.
State-level standing on Medicaid shows elevated but more mixed competitiveness: 87798 ranks #3 of 68 in-state (97th percentile; notably above typical state volume) and several other Medicaid codes rank in the 90th+ percentiles (for example, 87651 and 87641), while some Medicaid code ranks are more typical. Overall, the provider is a notable in-state player for molecular infectious-disease testing but with more variability across individual codes than its national Medicare profile.
The provider has a measurable COVID-19 testing footprint across Medicare and Medicaid billing: Medicare lists U0003 and 87635 among its top codes and 87635 is flagged as an "extreme outlier" (rank #48 of 9976, 100th percentile), while Medicaid U0003 ranks more modestly (43 of 197, 79th percentile; typical). This indicates capability and significant activity for SARS-CoV-2 molecular testing on certain code lines, though relative strength varies by specific COVID test codes.
Tenure is relatively recent but accompanied by rapid scale-up: the NPI was enumerated on 2019-04-17 (~7 years ago), and within that timeframe the provider has achieved national-scale billing concentrations (multiple 100th-percentile ranks and "extreme outlier" labels). That combination suggests a quickly scaled molecular diagnostics operation specialized in amplified nucleic acid testing.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
29 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 684,890 | $30 | $23.3M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 176,510 | $30 | $6M |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 44,560 | $30 | $1.5M |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 43,740 | $30 | $1.5M |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 43,190 | $30 | $1.5M |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 35,840 | $30 | $1.2M |
| 87493 | The lab analyst performs a test for Clostridium difficile toxin gene using an amplified nucleic acid probe technique. Clostridium difficile, also called C. diff, commonly causes hospital–acquired… | 20,250 | $40 | $749.2K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 21,040 | $30 | $715.2K |
| 87563 | he lab analyst performs a test on a patient specimen such as blood, for Mycoplasma genitalium antigen detection using amplified nucleic acid probe technique. | 16,630 | $30 | $565.5K |
| 87625 | The lab analyst performs a test to determine the presence of human papillomavirus. The provider uses nucleic acid detection for types 16 and 18, and 45 when performed. | 13,070 | $40 | $522.8K |
Showing 1–10 of 29
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 29 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
29 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 1 | 40 | 1,250 | $30 | $1.1M |
| 87481 | 1 | 20 | 940 | $30 | $574.2K |
| 87556 | 1 | 10 | 3,460 | $40 | $229.9K |
| 87653 | 1 | 20 | 360 | $30 | $175.8K |
| 81514 | 1 | 10 | 130 | $260 | $119.1K |
| 81226 | 4 | 10 | 220 | $440 | $117.7K |
| 87563 | 1 | 10 | 1,340 | $30 | $116K |
| 87505 | 1 | 10 | 900 | $130 | $112.5K |
| 87625 | 1 | 10 | 70 | $40 | $107.4K |
| 87541 | 2 | 10 | 180 | $30 | $98.1K |
Showing 1–10 of 29
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
44 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 19,770 | $30 | $533.7K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 10,420 | $10 | $114.6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 4,580 | $10 | $41.3K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 2,640 | $20 | $39.6K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 12,670 | $1 | $38K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 10,350 | $1 | $31K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 10,060 | $1 | $30.2K |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 3,740 | $10 | $26.2K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 7,920 | $1 | $15.8K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 3,680 | $1 | $14.7K |
Showing 1–10 of 44
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
44 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 43 | 200 | 990 | $70 | $517.5K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 17 | 60 | 110 | $220 | $151.2K |
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 3 | 10 | 110 | $40 | $149.3K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 10 | 30 | 220 | $30 | $139.6K |
| 81225 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 19, also known as CYP2C19. | 3 | 10 | 110 | $30 | $135.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 3 | 70 | 270 | $50 | $108.2K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 10 | 120 | 150 | $100 | $92.4K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 40 | 220 | 420 | $20 | $91.1K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 32 | 220 | 430 | $20 | $84.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 38 | 140 | 770 | $10 | $80.7K |
Showing 1–10 of 44
Other providers in the same ZIP code as Silverpath, Inc., ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Kencrest Services | PA | Intellectual & Developmental Disabilities Psychologist | $0 | $34.1M |
| Ethos Therapy Solutions, Inc. | PA | Durable Medical Equipment & Medical Supplies | $0 | $32.1M |
| Columbus Medical Services, LLC | PA | Case Management Agency | $0 | $25M |
| Malvern Community Health Services Inc. | PA | Clinic/Center | $0 | $11.8M |
| Wellness Coaches Usa LLC | PA | Clinical Medical Laboratory | $1M | $0 |
| Thomas Quinn | PA | Rheumatology Physician | $883.9K | $0 |
| Andrew Star | PA | Orthopaedic Surgery Physician | $674.8K | $0 |
| Vincent Quinn | PA | Cardiovascular Disease Physician | $511.4K | $0 |
| Telisha Ortiz | PA | Family Medicine Physician | $379.3K | $180 |
| Nando Addari | PA | Physical Therapist | $261.3K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.